Objective To narratively review the pathophysiological rationale of dual therapy with anti‐
calcitonin gene‐related peptide monoclonal antibodies and botulinum toxin type A in …

Background: OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal
antibodies (mAbs) target different migraine pathways, therefore, combination treatment may …

Introduction Combination use of onabotulinumtoxinA and calcitonin gene–related peptide
(CGRP) monoclonal antibodies (mAbs) has the potential to be more effective than either …

Background The approval of monoclonal antibodies for prevention of migraine has
revolutionized treatment for patients. Oral preventatives are still considered first line …

OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two
decades for chronic migraine prevention. The recently approved monoclonal antibodies …

Objective We sought to assess the safety and tolerability of 3 calcitonin gene‐related
peptide (CGRP) monoclonal antibodies in patients with chronic migraine who have failed …

Monoclonal antibodies (mAbs) acting on the calcitonin gene-related peptide (CGRP) or on
its receptor are new therapeutic biologics to prevent chronic migraine (CM). Four mAbs …

Introduction and objective Monoclonal antibodies targeting the calcitonin gene-related
peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical …

The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP)
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …

We sought to assess the effectiveness of combining dual therapy with onabotulinumtoxinA
(BTX) add-on to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti …